FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034433963> ?p ?o ?g. }

• W2034433963 endingPage "1698" @default.
• W2034433963 startingPage "1697" @default.
• W2034433963 abstract "HomeStrokeVol. 32, No. 7Hypertension in Acute Stroke: What to Do? Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUBHypertension in Acute Stroke: What to Do? Philip Bath Gudren Boysen Geoff Donnan Markku Kaste Kennedy R Lees Tom Olsen Karsten Overgaard Peter Sandercock Nils-Gunnar Wahlgren Philip BathPhilip Bath Division of Stroke Medicine, University of Nottingham, Nottingham, UK Search for more papers by this author Gudren BoysenGudren Boysen Department of Neurology, Bispebjerg Hospital, Copenhagen, Denmark Search for more papers by this author Geoff DonnanGeoff Donnan National Stroke Research Institute, Heidelberg, Australia Search for more papers by this author Markku KasteMarkku Kaste Department of Neurology, University of Helsinki, Helsinki, Finland Search for more papers by this author Kennedy R LeesKennedy R Lees Acute Stroke Unit, Western Infirmary, Glasgow, UK Search for more papers by this author Tom OlsenTom Olsen Department of Neurology, Gentofte University Hospital, Hellerup, Denmark Search for more papers by this author Karsten OvergaardKarsten Overgaard The Copenhagen Stroke Unit, Frederiksberg Hospital, Copenhagen, Denmark Search for more papers by this author Peter SandercockPeter Sandercock Department of Clinical Neurosciences, Western General Hospitals, Edinburgh, UK Search for more papers by this author Nils-Gunnar WahlgrenNils-Gunnar Wahlgren Department of Neurology, Karolinska Hospital, Stockholm, Sweden Search for more papers by this author Originally published1 Jul 2001https://doi.org/10.1161/01.STR.32.7.1697-aStroke. 2001;32:1697–1698To the Editor:Hypertension is common during the acute phase of stroke, and its management remains controversial. To explore this issue further, we held an ad hoc workshop at the World Stroke Conference, Melbourne, November 2000, and report here its discussion and conclusions.Hypertension is common (>50%) in both ischemic and hemorrhagic stroke, although its incidence depends on definitions and when and how blood pressure (BP) measurements are made. Hypertension is associated with a poor outcome,1 a relationship which is probably independent of stroke severity or clinical subtype. The cause of the negative relationship between BP and outcome is unclear but may relate to the development of reinfarction, cerebral edema, or hemorrhagic transformation.Our workshop agreed that trials are needed to test whether BP should be lowered in subjects with acute primary intracerebral hemorrhage. In contrast, significant differences of opinion existed on whether BP should be elevated or reduced in acute ischemic stroke. Existing data do not provide an answer: trials of beta receptor antagonists (β-RA) and some calcium channel blockers (CCB)—in which BP lowering occurred—and diaspirin cross-linked hemoglobin (which increases BP) were all complicated by worsened outcome in the treatment group.234567 It is unlikely that a single mechanism explains these findings, but CCB can reduce cerebral perfusion.89 We did not feel that the BP management strategy utilized in the NINDS and ECASS II thrombolysis trials1011 helped in deciding how to manage BP in general, because patients not treated with thrombolytics are a different population with a different natural history.A question that we could not answer was that of what agent should be used to alter BP, although the group agreed that differences between drug classes might be important and that extrapolating the findings of one class (eg, CCB) to other classes was inappropriate. Excluding β-RA and CCB (in which the existing data are not encouraging), small studies of angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, and nitric oxide donors have been completed or are underway.1213141516 These agents are multimodal in their action, thereby increasing the likelihood that efficacy trials might be positive; eg, angiotensin receptor antagonists will counteract the effects of activation of the renin-angiotensin system, nitrates will replace low vascular nitric oxide levels,17 and both are neuroprotective in experimental stroke. A phase II clinical trial of elevating BP (with dobutamine) is also underway in ischemic stroke.16 The group felt that any efficacy trial aiming to change BP would need to be of sufficient size to assess effects in subgroups, including subjects with or without prior hypertension and patients with different subtypes of stroke (eg, lacunar or cortical infarction).The method of delivery for any intervention was also discussed. We felt that intravenous formulations were not necessarily ideal because they would increase monitoring requirements, would be more susceptible to causing sudden or extreme changes in BP, and might delay or limit early mobilization and rehabilitation. Attractive routes of delivery included oral “melt” and transdermal preparations, both of which avoid problems with dysphagia, a common complication of acute stroke.Although we discussed when treatment should commence after stroke, current information does not give any guidance; trials of changing BP should factor this question into their design and analyses. We felt that treatment should continue for a week or so, a time period over which hypertension will settle in most patients and after which most clinicians are comfortable about initiating routine treatment.Although the ultimate question is to determine the effect of changing BP on functional outcome, studies are also required to assess the effect of vasoactive drugs on cerebral perfusion. Very few studies have been performed,18 and further (semi-)quantitative assessment is urgently required, eg, with positron emission tomography, single-photon emission CT, transcranial Doppler, MR perfusion and diffusion (with assessment of mismatch), quantitative CT perfusion, or xenon CT scanning. A further critical question is whether prior antihypertensive medication should be continued or stopped, since current practice varies.19 Once again, no randomized trial data exist, and it is vital that this question is examined, either as part of a BP modulation trial or separately.Workshop attendees are involved with ongoing trials,16 and we plan to meet again. References 1 Warlow CP, Dennis MS, van Gijn J, Hankey GJ, Sandercock PAG, Bamford JM, Wardlaw J. Stroke: A Practical Guide to Management. Oxford, UK: Blackwell Science; 1996.Google Scholar2 Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta blockade in acute stroke (“BEST” trial): an evaluation. BMJ.1988; 296:737–741.CrossrefMedlineGoogle Scholar3 Bridgers SL, Koch G, Munera C, Karwon M, Kurtz NM. Intravenous nimodipine in acute stroke: interim analysis of randomized trials. Stroke.1991; 22:153. Abstract.Google Scholar4 Wahlgren NG, MacMahon DG, de Keyser J, Indredavik B, Ryman T, for the INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis.1994; 4:204–210.CrossrefGoogle Scholar5 Kaste M, Fogelholm R, Erilä T, Palomaki H, Murros K, Rissanen A, Sarna S. A randomized, double-blind placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke.1994; 25:1348–1353.CrossrefMedlineGoogle Scholar6 Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J. The effects of lifarizine in acute cerebral infarction: a pilot study. Cerebrovasc Dis.1996; 6:156–160.CrossrefGoogle Scholar7 Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, Stern KN, Koudstaal PJ. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke.1999; 30:993–996.CrossrefMedlineGoogle Scholar8 Vorstrup S, Andersen A, Blegvad N, Paulson OB. Calcium antagonist (PY 108–068) treatment may further decrease flow in ischaemic areas in acute stroke. J Cereb Blood Flow Metab.1986; 6:222–229.CrossrefMedlineGoogle Scholar9 Lisk DR, Grotta JC, Lamki LM, Tran HD, Taylor JW, Molony DA, Barron BJ. Should hypertension be treated after acute stroke? A randomised controlled trial using single photon emission computed tomography. Arch Neurol.1993; 50:855–862.CrossrefMedlineGoogle Scholar10 Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, Marler JR, Tilley BC, for the NINDS rt-PA Stroke Study Group. Hypertension and its treatment in the NINDS rt-PA stroke trial. Stroke.1998; 29:1504–1509.CrossrefMedlineGoogle Scholar11 Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P, for the Second European-Australasian Acute Stroke Study Investigators. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet.1998; 352:1245–1251.CrossrefMedlineGoogle Scholar12 Waldemar G, Vorstrup S, Andersen A, Pedersen H, Paulson OB. Angiotensin converting enzyme inhibition and regional cerebral blood flow in acute stroke. J Cardiovasc Pharmacol.1989; 14:722–729.CrossrefMedlineGoogle Scholar13 Dyker AG, Grosset DG, Lees K. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke.1997; 28:580–583.CrossrefMedlineGoogle Scholar14 Lees KR. Effect of losartan on blood pressure, cerebral perfusion and renal function in patients following acute stroke. In: National Research Register. Leeds, UK: National Research Register; 2000.Google Scholar15 Bath PMW, Pathansali R, Iddenden R, Bath FJ. The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke. Cerebrovasc Dis. In press.Google Scholar16 Blood Pressure in Acute Stroke Collaboration (BASC). Interventions for deliberately altering blood pressure in acute stroke (Cochrane review). In: The Cochrane Library, issue 2, 2001. Oxford, UK: Update Software.Google Scholar17 Rashid P, Bath P. Plasma nitric oxide (nitrate) in stroke by type, severity and outcome. Stroke.2000; 31:532. Abstract.Google Scholar18 Mazumdar R, Bath F, Bath P. Vasoactive drugs on cerebral blood flow in acute ischaemic stroke. Stroke.2000; 31:135. Abstract.Google Scholar19 Bath PMW, Weaver C, Iddenden R, Bath FJ. Management of blood pressure immediately post stroke. Age Ageing.2000; 29:554–555.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Hadjiev D and Mineva P (2013) Elevated blood pressure management in acute ischemic stroke remains controversial: Could this issue be resolved?, Medical Hypotheses, 10.1016/j.mehy.2012.10.008, 80:1, (50-52), Online publication date: 1-Jan-2013. Giantin V, Semplicini A, Franchin A, Simonato M, Baccaglini K, Attanasio F, Toffanello E and Manzato E (2011) Outcome after acute ischemic stroke (AIS) in older patients: Effects of age, neurological deficit severity and blood pressure (BP) variations, Archives of Gerontology and Geriatrics, 10.1016/j.archger.2010.11.002, 52:3, (e185-e191), Online publication date: 1-May-2011. Gibson C, Coughlan T and Murphy S (2005) Glial nitric oxide and ischemia, Glia, 10.1002/glia.20143, 50:4, (417-426), Online publication date: 1-Jun-2005. Wong G and Chung C (2017) Acute Ischaemic Stroke: Management, Recent Advances and Controversies, Hong Kong Journal of Emergency Medicine, 10.1177/102490790401100107, 11:1, (35-52), Online publication date: 1-Jan-2004. Donnan G, Davis S and Thrift A (2003) The role of blood pressure lowering before and after stroke, Current Opinion in Neurology, 10.1097/00019052-200302000-00011, 16:1, (81-86), Online publication date: 1-Feb-2003. (2003) International Society of Hypertension (ISH), Journal of Hypertension, 10.1097/00004872-200304000-00003, 21:4, (665-672), Online publication date: 1-Apr-2003. Mansoor G and Frishman W (2002) Comprehensive Management of Hypertensive Emergencies and Urgencies, Heart Disease, 10.1097/00132580-200211000-00005, 4:6, (358-371), Online publication date: 1-Nov-2002. Spence J (2018) Hypertension and Stroke, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 10.1017/S0317167100120852, 29:2, (113-114), Online publication date: 1-May-2002. July 2001Vol 32, Issue 7 Advertisement Article InformationMetrics Copyright © 2001 by American Heart Associationhttps://doi.org/10.1161/01.STR.32.7.1697-a Originally publishedJuly 1, 2001 PDF download Advertisement" @default.
• W2034433963 created "2016-06-24" @default.
• W2034433963 creator A5009367881 @default.
• W2034433963 creator A5029838434 @default.
• W2034433963 creator A5039654978 @default.
• W2034433963 creator A5061586831 @default.
• W2034433963 creator A5065850779 @default.
• W2034433963 creator A5067364806 @default.
• W2034433963 creator A5074780950 @default.
• W2034433963 creator A5079574532 @default.
• W2034433963 creator A5079967649 @default.
• W2034433963 date "2001-07-01" @default.
• W2034433963 modified "2023-09-27" @default.
• W2034433963 title "Hypertension in Acute Stroke: What to Do?" @default.
• W2034433963 cites W2022098540 @default.
• W2034433963 cites W2038530616 @default.
• W2034433963 cites W2040786591 @default.
• W2034433963 cites W2043610467 @default.
• W2034433963 cites W2061673716 @default.
• W2034433963 cites W2068946282 @default.
• W2034433963 cites W2081406865 @default.
• W2034433963 cites W2098032054 @default.
• W2034433963 doi "https://doi.org/10.1161/01.str.32.7.1697-a" @default.
• W2034433963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11441226" @default.
• W2034433963 hasPublicationYear "2001" @default.
• W2034433963 type Work @default.
• W2034433963 sameAs 2034433963 @default.
• W2034433963 citedByCount "14" @default.
• W2034433963 countsByYear W20344339632013 @default.
• W2034433963 crossrefType "journal-article" @default.
• W2034433963 hasAuthorship W2034433963A5009367881 @default.
• W2034433963 hasAuthorship W2034433963A5029838434 @default.
• W2034433963 hasAuthorship W2034433963A5039654978 @default.
• W2034433963 hasAuthorship W2034433963A5061586831 @default.
• W2034433963 hasAuthorship W2034433963A5065850779 @default.
• W2034433963 hasAuthorship W2034433963A5067364806 @default.
• W2034433963 hasAuthorship W2034433963A5074780950 @default.
• W2034433963 hasAuthorship W2034433963A5079574532 @default.
• W2034433963 hasAuthorship W2034433963A5079967649 @default.
• W2034433963 hasBestOaLocation W20344339631 @default.
• W2034433963 hasConcept C126322002 @default.
• W2034433963 hasConcept C127413603 @default.
• W2034433963 hasConcept C164705383 @default.
• W2034433963 hasConcept C2776572282 @default.
• W2034433963 hasConcept C2780645631 @default.
• W2034433963 hasConcept C3020166492 @default.
• W2034433963 hasConcept C71924100 @default.
• W2034433963 hasConcept C78519656 @default.
• W2034433963 hasConceptScore W2034433963C126322002 @default.
• W2034433963 hasConceptScore W2034433963C127413603 @default.
• W2034433963 hasConceptScore W2034433963C164705383 @default.
• W2034433963 hasConceptScore W2034433963C2776572282 @default.
• W2034433963 hasConceptScore W2034433963C2780645631 @default.
• W2034433963 hasConceptScore W2034433963C3020166492 @default.
• W2034433963 hasConceptScore W2034433963C71924100 @default.
• W2034433963 hasConceptScore W2034433963C78519656 @default.
• W2034433963 hasIssue "7" @default.
• W2034433963 hasLocation W20344339631 @default.
• W2034433963 hasLocation W20344339632 @default.
• W2034433963 hasOpenAccess W2034433963 @default.
• W2034433963 hasPrimaryLocation W20344339631 @default.
• W2034433963 hasRelatedWork W2125385597 @default.
• W2034433963 hasRelatedWork W2332493923 @default.
• W2034433963 hasRelatedWork W2369736773 @default.
• W2034433963 hasRelatedWork W2418884372 @default.
• W2034433963 hasRelatedWork W2466337536 @default.
• W2034433963 hasRelatedWork W2509873459 @default.
• W2034433963 hasRelatedWork W2531650028 @default.
• W2034433963 hasRelatedWork W2610244227 @default.
• W2034433963 hasRelatedWork W2925008124 @default.
• W2034433963 hasRelatedWork W3017570460 @default.
• W2034433963 hasVolume "32" @default.
• W2034433963 isParatext "false" @default.
• W2034433963 isRetracted "false" @default.
• W2034433963 magId "2034433963" @default.
• W2034433963 workType "article" @default.